We would love to hear your thoughts about our site and services, please take our survey here.
A doubling of the SP from here wouldn't be great considering we were at £5 twice over the last 2 yrs.
Appreciate there has been some dilution but given the optimistic outlook around Bex should we not be looking at more?
I can see the issue of more significant data being the catalyst for the much awaited rerate.
Thus data is what I believe he needs to get the deal he wants.
When and what that is the million dollar question
So a lot of people are asking how about the partnering. We know that this could become a significant partner opportunity, but we don't want to do this yet. We'd like to obtain additional data really to generate the value for the shareholders. I have collected here a few examples. You have heard about CD47 company, EUR 5 billion Pfizer bought another one for EUR 2 billion, anti-CD47 never demonstrated a single agent activity as bexmarilimab has shown.
The BOD tried to reassure shareholders with 2 RNSs which didn't work.
Nothing will push this back up significantly unless it's a cease in hostilities or an update on any sale.
I guess the the update in any sale would need reassurance that payment is not affected by sanctions.
Not much to ask for on both counts ;-)
I think many thought 10€ would be here by now.
Was hoping for £15-£20 a while back so £10 might now be the compromise unless you are prepared to wait much longer.
Did they not say even 10€ might be late 2024